In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Manufacturing Focus

Re-Configuring Pharma Operations Amid Pandemic Strains

Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.

Innovation Manufacturing

JCR Pharma: Crossing Oceans And The Blood-Brain Barrier

After 45 years as a domestic Japanese biopharmaceutical company, JCR Pharmaceuticals is expanding into global markets. The company is betting that its manufacturing strength – which helped land a COVID-19 vaccine manufacturing deal with AstraZeneca – and blood-brain barrier crossing J-Brain Cargo technology will lead to success in Western markets.   

Japan Business Strategies

Do It Yourself: Advantages Of Internal Gene Therapy Manufacturing

The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?

Manufacturing Gene Therapy

BTG SP Makes A Virtue Of Manufacturing And Supply Discipline Despite COVID

Manufacturing and supply chain resilience ensured that BTG Specialty Pharma met its sales target in the COVID-affected 2020. Its president, Anthony Higham, explained how this was possible while the company busily  ̶  and quietly – sought new ownership, and all under the shadow of Brexit.

Business Strategies Innovation

The 14 Billion Dose COVID-19 Manufacturing Challenge

Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.

Commercial Coronavirus COVID-19

Will India’s $3bn Incentive Schemes Yield A $41bn Dividend?

An new $2.1bn incentive scheme for formulations follows on from an earlier scheme for APIs in India. Experts weigh in on the likelihood of industry participation and whether this $3bn push will result in $41bn of incremental sales for the industry while strengthening supply chains in a post-COVID world. 

Business Strategies Commercial

When You Can’t Win For Losing: Kodak And The Reshoring Of US Pharmaceutical Manufacturing

Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.

Business Strategies Ingredients

Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend

Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.

Manufacturing Policy

Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack

Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.

Commercial Coronavirus COVID-19
Read More
UsernamePublicRestriction

Register